{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ledipasvir+90+MG&page=2", "query": { "intervention": "Ledipasvir 90 MG", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ledipasvir+90+MG&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ledipasvir+90+MG&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T14:07:52.701Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01701401", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 870, "start_date": "2012-09", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701401" }, { "nct_id": "NCT01938430", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic HCV Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 339, "start_date": "2013-09", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 30, "location_summary": "Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01938430" }, { "nct_id": "NCT03312023", "title": "Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]", "type": "DRUG" }, { "name": "Sofosbuvir 400 MG [Sovaldi]", "type": "DRUG" }, { "name": "Ledipasvir 90 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-02-01", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03312023" }, { "nct_id": "NCT02073656", "title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus", "HIV" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2014-02", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073656" }, { "nct_id": "NCT02605304", "title": "12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection", "Hepatitis C" ], "interventions": [ { "name": "Ledipasvir/sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2016-02-17", "completion_date": "2017-03-20", "has_results": true, "last_update_posted_date": "2018-05-02", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 2, "location_summary": "San Francisco, California • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605304" }, { "nct_id": "NCT01984294", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic HCV Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "GS-9669", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2013-10", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984294" }, { "nct_id": "NCT02128217", "title": "Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infection", "Hepatitis" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Ledipasvir/Sofosbuvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2014-05-30", "completion_date": "2017-05-09", "has_results": true, "last_update_posted_date": "2018-04-27", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 12, "location_summary": "San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02128217" }, { "nct_id": "NCT02350569", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-05-22", "completion_date": "2016-04-22", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 6, "location_summary": "San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02350569" }, { "nct_id": "NCT02301936", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-03-02", "completion_date": "2016-04-18", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 1, "location_summary": "Lutherville, Maryland", "locations": [ { "city": "Lutherville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02301936" }, { "nct_id": "NCT02786537", "title": "Study of Oral Treatments for Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "SOF/LDV (sofosbuvir/ledipasvir)", "type": "DRUG" }, { "name": "PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)", "type": "DRUG" }, { "name": "EBR/GZR (elbasvir/grazoprevir)", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1275, "start_date": "2016-06", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-12-06", "last_synced_at": "2026-10-05T14:07:52.701Z", "location_count": 38, "location_summary": "Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02786537" } ] }